TI
PTGX icon

Trexquant Investment’s Protagonist Therapeutics PTGX Stock Holding History

Trexquant Investment’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,018
Closed -$1.99M – 1843
2025
Q2 		$1.99M Sell
36,018
-67,965
-65% -$3.26M 0.02% 885
2025
Q1 		$5.03M Buy
103,983
+11,195
+12% +$469K 0.06% 501
2024
Q4 		$3.58M Buy
92,788
+69,697
+302% +$3.04M 0.04% 646
2024
Q3 		$1.04M Sell
23,091
-57,523
-71% -$2.32M 0.01% 1039
2024
Q2 		$2.79M Sell
80,614
-21,765
-21% -$637K 0.04% 610
2024
Q1 		$2.96M Buy
+102,379
New +$2.79M 0.06% 501
2023
Q3 		– Sell
-11,413
Closed -$315K – 1742
2023
Q2 		$315K Buy
+11,413
New +$286K 0.01% 1178
2022
Q4 		– Sell
-22,421
Closed -$189K – 1662
2022
Q3 		$189K Buy
+22,421
New +$212K 0.01% 1205
2022
Q2 		– Sell
-9,795
Closed -$232K – 1799
2022
Q1 		$232K Buy
+9,795
New +$276K 0.01% 1135
2021
Q2 		– Sell
-10,522
Closed -$273K – 1421
2021
Q1 		$273K Sell
10,522
-7,552
-42% -$191K 0.03% 805
2020
Q4 		$364K Buy
+18,074
New +$389K 0.04% 583
2020
Q3 		– Sell
-10,707
Closed -$189K – 1477
2020
Q2 		$189K Sell
10,707
-9,774
-48% -$123K 0.01% 1058
2020
Q1 		$145K Buy
+20,481
New +$153K 0.01% 1013
2019
Q1 		– Sell
-18,317
Closed -$123K – 1246
2018
Q4 		$123K Sell
18,317
-11,263
-38% -$89.3K 0.01% 978
2018
Q3 		$304K Buy
+29,580
New +$255K 0.02% 684
2018
Q2 		– Sell
-22,506
Closed -$193K – 1141
2018
Q1 		$193K Buy
22,506
+5,400
+32% +$102K 0.01% 957
2017
Q4 		$356K Buy
+17,106
New +$303K 0.04% 664

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Trexquant Investment's PTGX Position: Q3 2025 in Review

Trexquant Investment sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 36,018 shares — an estimated $1.99M sold.

Trexquant Investment first reported a position in PTGX in Q4 2017 and held it in 17 quarters. The position peaked at $5.03M in Q1 2025. 274 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • Trexquant Investment reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Trexquant Investment sold 36,018 Protagonist Therapeutics shares in Q3 2025, an estimated $1.99M.
  • Trexquant Investment first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 17 quarters.
  • Trexquant Investment's Protagonist Therapeutics position peaked at $5.03M in Q1 2025.
  • 274 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Trexquant Investment's 13F filing for Q3 2025, filed 14 Nov 2025.